RecruitingPhase 2

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Egypt46 participantsStarted 2025-03-01

Plain-language summary

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography Exclusion Criteria: * Pregnant and/or lactating women * Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women) * Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis. * patients suffering from chronic kidney disease, and hyper/hypoparathyroidism * Hypersensitivity to carbocistiene.

What they're measuring

The change in the degree of steatosis in the Ultra Sound

Timeframe: 3 months

Trial details

NCT IDNCT06863376

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-03-20

View on ClinicalTrials.gov More Non-Alcoholic Fatty Liver Disease trials